SITC 2022: Jumpstart Spatial Signature Development

Showcasing PhenoCode Signature Panels

Missed us at SITC 2022? Not to worry. Find below all the exciting new developments Akoya presented at SITC 2022.

Akoya launched the new PhenoCode Signature Panels at SITC 2022. The big reveal happened at our dinner symposium on the first day of the conference in Boston on November 10th. Our panel of speakers presented about our new multiplex PhenoCode Signature panels based on novel protein chemistry that can accelerate the development of spatial signatures.

Supercharging Spatial Signature Development: Predictive Biomarkers for the Ever-Changing Immunotherapy Landscape

Oliver Braubach

Acclerating the Development of Spatial Signatures

Oliver Braubach, PhD
Director of Applications,
Akoya Biosciences
Patrick Savickas

Vision for Success: Adopting High-plex Assay for Drug Development

Patrick Savickas
Lead Scientist,
HistoWiz
Arutha Kulasinghe

Decoding Immunotherapy Resistance: A multiomic Approach

Arutha Kulasinghe, PhD
NHMRC Research Fellow and Group Leader,
University of Queensland
484ee9bae78627bcc9fb0acd7bfac004

Akoya also presented several poster highlighting PhenoCode Signature Panels design, development and validation, the complementary aspect of these panels to comprehensively characterize the TME and how these panels integrate into a discovery to translation workflows to develop spatial signatures. In addition, Akoya also showcased 2 poster featuring the ultra-high plex profiling capabilities of the PhenoCycler Fusion for the unbiased spatial analysis of glioblastoma and Cutaneous Squamous Cell Carcinomas.

Download Posters

Complete the registration form to download these poster.

Posters to Check Out

Poster #160 | Novel, high-plex, and flexible biomarker panels for rapid development of spatial signatures to improve stratification of response to combination therapies

Authors: Rachel Schaefer1, Jacob Circelli1, Oscar Perez1, Linying Liu1, Michael McLane1, Yi Zheng1
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA

Poster #120 | Decoding Immunotherapy Responses with High-dimensional and High-throughput Spatial Phenotyping of Non-small cell Lung Cancer (NSCLC)

Authors: Ning Ma1, Aditya Pratapa1, James Monkman2, Ken O’Byrne3, Oliver Braubach1, Arutha Kulasinghe2
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
2University of Queensland, Brisbane, QLD, Australia
3Princess Alexandra Hospital, Brisbane, QLD, Australia

Poster #149 | Complementary PhenoCode Signature Panels comprehensively map cell interactions and identify Spatial Phenotypic Signatures in the tumor microenvironment

Authors: Bethany Remeniuk1, Bei Hopkins1, Natalie Monteiro1, Darren Locke1
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA

Poster #131 | Quantitative spatial profiling of the tumor microenvironment in NSCLC tissue microarray cores using 6-plex multiplex imaging technology and AI-powered phenotyping analysis

Authors: Nicole Couper1, Bethany Remeniuk2, Karen McClymont1, Bei Hopkins2, Natalie Monteiro2, Lorcan Sherry1, Darren Locke2
1OracleBio Ltd, Glasgow, Scotland, UK
2Akoya Biosciences, Inc, Marlborough, Massachusetts, USA

Poster #116 | Deep high-plex spatial phenotyping of Glioblastoma multiforme provides new insights into the immune landscape and tumor heterogeneity

Authors: Dmytro Klymyshyn1, Niyati Jhaveri1, Oliver Braubach1, Subham Basu3, Michael Prater3, Keith L. Black2 & Tao Sun2
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
2Department of Neurosurgery, Cedars-Sinai Medical Center. 8700 Beverly Blvd, Los Angeles, CA 90048
3Abcam, Biomedical Campus, Discovery Drive, Trumpington, Cambridge CB2 0AX, United Kingdom

Poster #79 | High-dimensional spatial phenotyping of cutaneous squamous cell carcinoma from immune-competent and immunocompromised patients

Authors: Arutha Kulasinghe2, Niyati Jahveri3, Dmytro Klymyshyn3, Bassem Ben Cheikh3, Rahul Ladwa1, Howard Liu1, Caroline Cooper1, Gabrielle Belz2, Subham Basu4, Michael Prater4, Oliver Braubach2, Sandro Porceddu1
1Princess Alexandra Hospital, Brisbane, QLD, Australia
2University of Queensland, Brisbane, QLD, Australia
3Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
4Abcam, Biomedical Campus, Discovery Drive, Trumpington, Cambridge CB2 0AX, United Kingdom